SCNI News and Press, Scanner Technologies Corp From 12/29/23

Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds PR Newswire JERUSALEM , Dec. 29, 2023 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused both on developme...

Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on the development of both inflammation and immunology. During the webinar, SCNI CEO Amir Reichman will present an overview of the company’s performance throughout the year 2023, along with a discussio...

Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9 PR Newswire JERUSALEM , Dec. 27, 2023 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company focused both on development of inflammation and immunolo...

A recent paper that was published in the  “Nature"  journal has redefined rheumatoid arthritis (RA) and potentially opened the door to the development of targeted therapies. Researchers analyzed tissue collected from the synovial joints of almost 80 people diagnosed with moder...

Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products, has announced successful preclinical trial results of its innovative anti ...

Scinai Announces Promising Results in a Psoriatic Human Skin Model PR Newswire JERUSALEM , Dec. 12, 2023 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI), a biopharmaceutical company focused on development of inflammation and immunology biologica...

Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products, is announcing the publication of a peer-reviewed article regarding NanoAbs. Th...

Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug PR Newswire Data backs use of Scinai's aerosolized NanoAbs as a platform for the treatment of hyperinflammatory viral diseases...

Many infectious disease specialist fellowship programs across the country remain unfulfilled with only 74% of ID fellowship positions and 56% of ID fellowship programs being filled on Match Day. The Infectious Diseases Society of America (IDSA) notes that the overall number of infectious diseas...

Scinai Immunotherapeutics (NASDAQ: SCNI) today announced the execution of a formal amendment to its finance contract with the European Investment Bank (“EIB”). According to the announcement, the amendment extends the maturity date of the contract by four years from Dec. 31, 2027, t...